.png)
.png)
OBJECTIVE: We aimed to show the impacts of peritoneal dialysis and hemodialysis replacement therapies on insulin resistance which can provide important contribution to the risk for development of atherosclerosis and cardiovascular disease.
MATERIAL and METHODS: Peritoneal dialysis and hemodialysis patients, who have similar demographic and clinical characteristics, followed-up and treated regularly in the same clinic for at least one year, were included in the study. The patients with hypertension, diabetes, acute – chronic infection and obeses were excluded. Diagnosis of diabetes mellitus and presence of acute-chronic infection in the patients were exclusion criteria.
RESULTS: When peritoneal dialysis and hemodialysis patients which have similar duration of dialysis, age, gender, distribution and adequate dialysis compared with serum homocysteine levels, it is found to be higher in both of patient groups. While serum LDL-cholesterol level was determined to be higher in peritoneal dialysis patient group, no difference was determined between peritoneal dialysis and hemodialysis patient groups regarding presence of insulin resistance.
CONCLUSION: Proper patient selection and administrating appropriate treatment beginning from the first year, we think that dialysis replacement therapies have no superiority to each other regarding the development of morbidity and mortality.